Shayne Heffernan has issued a strong buy on BioSante Pharmaceuticals, Inc. NASDAQ:BPAX with a $10 price target in 2011.
A jump in cash reserves of $6m at BioSante Pharmaceuticals, Inc. NASDAQ:BPAX combined with insiders continued buying and the upcoming tests of their drugs all point to big things happening at BioSante Pharmaceuticals, Inc. NASDAQ:BPAX.
BioSante Pharmaceuticals, Inc. (BioSante) is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism.
The Company’s products for female sexual health, menopause, contraception and male hypogonadism include LibiGel, a once daily transdermal testosterone gel in Phase III clinical development under a special protocol assessment (SPA) for the treatment of female sexual dysfunction (FSD); Elestrin, a once daily transdermal estradiol (estrogen) gel indicated for the treatment of moderate-to-severe vasomotor symptoms;
The Pill-Plus (triple component contraceptive), a once daily use of various combinations of estrogens, progestogens and androgens in development for the treatment of female sexual dysfunction (FSD) in women using oral or transdermal contraceptives, and Bio-T-Gel, a once daily transdermal testosterone gel in development for the treatment of hypogonadism, or testosterone deficiency, in men.
No comments:
Post a Comment